Table 2 Demographic and clinical characteristics of lymphoma patients with and without VTE

Age, median (range)

56 (18–87)

54 (19–89)

0.898

Men/women

337/300

37/32

0.900

Hemoglobin, g/L, median (range)

124 (51–172)

117 (87–141)

0.017

Leukocytes, ×10⁹/L, median (range)

7.4 (0.4–28.5)

8.5 (4.6–16.6)

0.132

Platelets, ×10⁹/L, median (range)

248 (29–613)

283 (103–678)

0.034

NLR, median (range)

2.7 (0.2–32.5)

3.79 (0.7–160.5)

0.001

PLR, median (range)

10.1 (0.3–193.3)

14.5 (483.3)

0.001

ESR, mm/h, median (range)

26 (2–150)

38 (2–150)

0.023

CRP, mg/L, median (range)

9.9 (0.1–274.6)

30.6 (0.8–251.8)

< 0.001

Fibrinogen, mg/L, median (range)

5.3 (1–13.2)

5.7 (1.9–11.8)

0.351

LDH > reference range limit, n (%)

187 (30.4)

32 (50.8)

0.001

TP < reference range limit, n (%)

258 (40.5)

39 (56.6)

0.024

Albumin < reference range limit, n (%)

70 (11)

15 (21.2)

0.032

B symptomatology, n (%)

360 (56.6)

52 (75.4)

0.001

“Bulky” tumor mass, n (%)

182 (28.5)

34 (49.3)

< 0.001

Extranodal localization, n (%)

368 (57.8)

35 (50.7)

0.259

Mediastinal involvement, n (%)

189 (29.6)

32 (46.4)

0.004

IPI > 1, n (%)

153 (52.0)

27 (71.1)

0.027